(Box of 6 Allogeneic PRP Vials)

This product is intended for use by medical professionals only. If you are an active licensed physician and wish to place an order please contact our team to create an account before placing an order.

Allogeneic PRP vs autologous PRP

While autologous PRP has been widely used and has demonstrated safety and effectiveness in the treatment of various wounds  and soft tissue injuries, it has some limitations. One of the primary limitations of autologous PRP is that it requires the harvesting  of a patient’s own blood, which is not feasible or safe in all cases. For example, elderly patients, neonates, or individuals unable  to donate large quantities of blood may not be able to undergo the procedure. Additionally, the quality and quantity of platelets  obtained from a patient’s own blood can vary depending on factors such as age, health status, and medication use.  

Allogeneic PRP, on the other hand, is obtained from a donor and can be used as an off-the-shelf therapy for wound repair and  musculoskeletal injuries. This eliminates the need for blood harvesting from the patient, making it a more convenient and feasible  option for a broader range of patients. Additionally, allogeneic PRP can provide a more standardized and consistent product, as  the platelet concentration and quality can be controlled during the manufacturing process.  

Furthermore, allogeneic PRP can provide greater amounts of platelet-derived bioactive factors, including growth factors and  cytokines, which can promote tissue repair and regeneration. This is because allogeneic PRP is often prepared from a pool of 

donors, allowing for a higher concentration of platelets and bioactive factors to be obtained than can be possible with autologous  PRP. In addition, allogeneic PRP contains a more diverse array of bioactive factors, as different donors have variations in their  platelet composition.  

Allogeneic PRP is less costly and time-consuming than autologous PRP, as it eliminates the need for blood harvesting and  processing from the patient. This makes the treatment more accessible to patients and healthcare providers.

Download our Cellgenic Allogeneic PRP brochure

  • This field is for validation purposes and should be left unchanged.

Sourcing and Preparation

Allogeneic PRP has been shown to be a safe option. Allogeneic PRP offers the benefit of being collected from voluntary blood  donors, with its derivatives ready for use without requiring clinicians to collect a sample from the patient. This is particularly useful  in clinical situations such as acute burns when patients may be fluid-depleted and thrombocytopenic. However, PRP preparation  is contraindicated in patients with haematological disorders, sepsis, or infection, and relative contraindications include the use of  non-steroidal anti-inflammatory drugs or corticosteroids, tobacco use, malignancies, and anaemia.  

The preparation of PRP involves various protocols that describe the speed, time, temperature of centrifugation, and type of  anticoagulant used. These variations affect the yield of bioactive material and make it difficult to compare the efficacy of PRP. The  most common PRP preparation method involves taking a whole blood sample through venipuncture into a container coated with  citrate anticoagulant. The centrifuge settings impact the concentration of platelets, which remains widely variable in clinical  studies, without a clear consensus on an optimal regime for maximizing platelet yield. Different classes of PRP are available, and  a multi-disciplinary consensus conference published 4 main families of preparations depending on their leukocyte and fibrin  content. An improved classification system has also been suggested to facilitate the comparison of clinical studies and promote  further progression in its application in the regenerative medicine field. 

Allogeneic PRP can also

  • Accelerate endothelial, epithelial, and epidermal regeneration.

  • Stimulate angiogenesis.

  • Enhance collagen synthesis.

  • Promotes enhanced soft tissue wound healing.

  • Decreased dermal scarring.

  • Reverse the inhibition of wound healing caused by glucocorticoids.

  • High leukocyte concentration adding an antimicrobial effect.

  • The native fibrinogen concentration imparts a gelatinous adhesive consistency, for ease of surgical  application.

  • Provides a watertight seal (necessary for dural closures).

  • When mixed with crushed coral or crushed bone fragments it forms a putty ideal for packing or structural  reconstructions.

  • Augmented rate of extracellular matrix deposition, resulting in earlier wound closure.

  • Autologous blood product, with no risk of infectious disease transmission or clerical errors, thus making it  a safe product.

  • No time consuming visits to the blood bank for pre-donation. Sequester is done in the immediate  preoperative period, and utilized perioperatively.

  • Provides for an immediate surgical hemostatic agent that is biocompatible, effective and safe.

Safety and Efficacy

Numerous clinical studies have demonstrated the efficacy of Allogeneic PRP Therapy in treating a wide range  of conditions

Allogeneic PRP possesses beneficial effects against cognitive aging and it can be used as a novel self-sourced  treatment in age-related cognitive decline.

 PRP treatment ameliorates skin photoaging through regulation of MMP-1, tyrosinase, fibrillin and  tropoelastin expression.

Use of allogeneic PRP shows promise for the treatment of bone defect with negligible immunogenicity,  great healing efficacy, potentially more consistent quality, and no additional health burden to patients.

PRP significantly improved wound healing in chronic diabetic ulcers, venous ulcers, pressure ulcers, leprosy  ulcers, acute traumatic wounds, and ulcers of multifactorial etiologies.

PRP injection is a safe and effective treatment for RC cuff injury in patients who have failed conservative  treatment.

The use of allogenic PRP provides a feasible, effective, and safe biological therapy as an off-the-shelf  solution for diabetic lower extremity ulcers.

Get it Touch!

  • This field is for validation purposes and should be left unchanged.


Global Stem Cells Group Inc Datran Center 9100 S Dadeland Boulevard, Suite 1500. Miami Fl. 33156 United States


+1 305 560 5337





Open chat
Need Help?
Can we help you?